StreetInsider.com News Articles

PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies

Wed, 07 Oct 2026 08:00:00 -0400

The network is designed to bring together pharmacies, hospitals, contract manufacturers and government facilities to make personalized, rare disease, discontinued and short-supply medicines and emergency countermeasures, close to the patients who need them.

Toronto, Ontario--(Newsfile Corp. - October 7, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company advancing 3D-printed medicines, today announced the launch of the M3DICINES™ National Network Program (the "Network Program"). The program will build a national network of qualified sites that make personalized medicines on CraftMake™ pharmaceutical 3D printers, supported by PharmaTher's M3DICINES™ platform.

The network starts with U.S. 503A compounding pharmacies

PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies

Wed, 07 Oct 2026 08:00:00 -0400

The network starts with U.S. 503A compounding pharmacies

PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies

Wed, 07 Oct 2026 08:00:00 -0400

The network starts with U.S. 503A compounding pharmacies

PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies

Wed, 07 Oct 2026 08:00:00 -0400

The network starts with U.S. 503A compounding pharmacies

PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES

Mon, 05 Oct 2026 08:00:00 -0400

Highlights

M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply.
Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.
Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine dissolvable tablet for telehealth in Q1 2027.
Rare pediatric NDA with voucher potential. Orphan drug and rare pediatric disease designation applications are planned for October 2026, with a pre-IND meeting in Q1 2027 and an NDA submission

PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES

Mon, 05 Oct 2026 08:00:00 -0400

Highlights

M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply.
Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.
Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine dissolvable tablet for telehealth in Q1 2027.
Rare pediatric NDA with voucher potential. Orphan drug and rare pediatric disease designation applications are planned for October 2026, with a pre-IND meeting in Q1 2027 and an NDA submission

PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES

Mon, 05 Oct 2026 08:00:00 -0400

Highlights

M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply.
Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.
Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine dissolvable tablet for telehealth in Q1 2027.
Rare pediatric NDA with voucher potential. Orphan drug and rare pediatric disease designation applications are planned for October 2026, with a pre-IND meeting in Q1 2027 and an NDA submission

PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES

Mon, 05 Oct 2026 08:00:00 -0400

Highlights

M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply.
Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.
Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine dissolvable tablet for telehealth in Q1 2027.
Rare pediatric NDA with voucher potential. Orphan drug and rare pediatric disease designation applications are planned for October 2026, with a pre-IND meeting in Q1 2027 and an NDA submission

PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform

Thu, 01 Oct 2026 08:00:00 -0400

Agreement opens the U.S. and Canadian markets across all customer segments and lays the foundation for PharmaTher's personalized 503A products, FDA rare disease program, national emergency and medical countermeasures initiatives, and CDMO and white-label services

Highlights

PharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations, consumables, and service.
Exclusivity covers every key customer segment: compounding pharmacies (503A and 503B), telehealth and digital health companies, CDMOs, hospitals, academic, research, and government institutions, and pharmaceutical, biotechnology, and healthcare companies.
PharmaTher estimates more than 10,000 potential placement sites in North America. Each placement is

PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform

Thu, 01 Oct 2026 08:00:00 -0400

Highlights

PharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations, consumables, and service.
Exclusivity covers every key customer segment: compounding pharmacies (503A and 503B), telehealth and digital health companies, CDMOs, hospitals, academic, research, and government institutions, and pharmaceutical, biotechnology, and healthcare companies.
PharmaTher estimates more than 10,000 potential placement sites in North America. Each placement is

PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform

Thu, 01 Oct 2026 08:00:00 -0400

Highlights

PharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations, consumables, and service.
Exclusivity covers every key customer segment: compounding pharmacies (503A and 503B), telehealth and digital health companies, CDMOs, hospitals, academic, research, and government institutions, and pharmaceutical, biotechnology, and healthcare companies.
PharmaTher estimates more than 10,000 potential placement sites in North America. Each placement is

PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform

Thu, 01 Oct 2026 08:00:00 -0400

Highlights

PharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations, consumables, and service.
Exclusivity covers every key customer segment: compounding pharmacies (503A and 503B), telehealth and digital health companies, CDMOs, hospitals, academic, research, and government institutions, and pharmaceutical, biotechnology, and healthcare companies.
PharmaTher estimates more than 10,000 potential placement sites in North America. Each placement is

Medicus Pharma completes $2.97 million acquisition of Antev Limited

Tue, 02 Sep 2025 07:32:11 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) has completed its acquisition of 98.6% of the issued and outstanding shares of Antev Limited for approximately $2.97 million in cash and 1,603,164 common shares of Medicus, according to a company statement.

Antev, a UK-based clinical-stage drug development company, is developing Teverelix, a GnRH antagonist for acute urinary retention and prostate cancer treatment in patients with high cardiovascular risk. Former Antev shareholders are entitled to receive up to approximately $65 million in additional contingent consideration tied to potential future FDA Phase 2 and New Drug Application approvals.

Patrick J. Mahaffy, former chairman of Antev and former CEO

Medicus Pharma completes $2.97 million acquisition of Antev Limited

Tue, 02 Sep 2025 07:32:11 -0400

Patrick J. Mahaffy, former chairman of Antev and former CEO

Medicus Pharma completes $2.97 million acquisition of Antev Limited

Tue, 02 Sep 2025 07:32:11 -0400

Patrick J. Mahaffy, former chairman of Antev and former CEO

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Tue, 02 Sep 2025 07:30:00 -0400

Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunity